Novel genetic variants associated with lumbar disc degeneration in northern Europeans: A meta-analysis of 4600 subjects by Williams, F.M.K. (Frances) et al.
EXTENDED REPORT
Novel genetic variants associated with lumbar disc
degeneration in northern Europeans: a meta-analysis
of 4600 subjects
Frances M K Williams,1 Aruna T Bansal,2 Joyce B van Meurs,3,4 Jordana T Bell,1
Ingrid Meulenbelt,4,5 Pradeep Suri,6 Fernando Rivadeneira,3,4 Philip N Sambrook,7
Albert Hofman,8 Sita Bierma-Zeinstra,9 Cristina Menni,1 Margreet Kloppenburg,10
P Eline Slagboom,4,5 David J Hunter,7 Alex J MacGregor,1 Andre G Uitterlinden,3
Tim D Spector1
▸ Additional data are
published online only. To view
this file please visit the journal
online (http://dx.doi.org/10.
1136/annrheumdis-2012-
201551).
For numbered affiliations see
end of article.
Correspondence to
Dr Frances M K Williams,
Department Twin Research
and Genetic Epidemiology,
King’s College London,
St Thomas Hospital,
Westminster Bridge Road,
London SE1 7EH, UK;
frances.williams@kcl.ac.uk
ATB and JBM contributed
equally.
Accepted 19 July 2012
Published Online First
19 September 2012
ABSTRACT
Objective Lumbar disc degeneration (LDD) is an
important cause of low back pain, which is a common
and costly problem. LDD is characterised by disc space
narrowing and osteophyte growth at the circumference of
the disc. To date, the agnostic search of the genome by
genome-wide association (GWA) to identify common
variants associated with LDD has not been fruitful. This
study is the first GWA meta-analysis of LDD.
Methods We have developed a continuous trait based
on disc space narrowing and osteophytes growth which
is measurable on all forms of imaging (plain radiograph,
CT scan and MRI) and performed a meta-analysis of five
cohorts of Northern European extraction each having
GWA data imputed to HapMap V.2.
Results This study of 4600 individuals identified four
single nucleotide polymorphisms with p<5×10−8, the
threshold set for genome-wide significance. We identified
a variant in the PARK2 gene (p=2.8×10−8) associated
with LDD. Differential methylation at one CpG island of
the PARK2 promoter was observed in a small subset
of subjects (β=8.74×10−4, p=0.006).
Conclusions LDD accounts for a considerable
proportion of low back pain and the pathogenesis of
LDD is poorly understood. This work provides evidence
of association of the PARK2 gene and suggests that
methylation of the PARK2 promoter may influence
degeneration of the intervertebral disc. This gene has
not previously been considered a candidate in LDD and
further functional work is needed on this hitherto
unsuspected pathway.
INTRODUCTION
Lumbar disc degeneration (LDD) is a common,
age-related trait:1 over a third of middle aged
women have at least one degenerate disc. LDD
contributes to low back pain2 3 and as low back
pain is common in the general population and
costly to society,4 LDD is of considerable public
health importance. Discrete biochemical, histo-
logical, metabolic and functional changes occur in
LDD, such that discs become dehydrated, lose disc
height and there is accompanying outgrowth of
osteophytes from the vertebral body margin.5
There are similarities with peripheral joint
osteoarthritis (OA). LDD has been shown to be
heritable, with estimates of 65%–80%6 7 and so a
considerable proportion of the variance in LDD is
explained by genetic factors. Yet to date, candidate
gene studies have detected only a small number of
convincing associations of genetic variants with
LDD (reviewed by Ryder et al8). A number of
studies show conflicting results: these are likely
due to small sample size or may reflect ethnic dif-
ferences between Northern European and Asian
populations, as seen in OA.9 That some published
genome-wide associations (GWAs) in common
complex traits fail to replicate candidate gene find-
ings suggests limitations to the candidate gene
method.10 As in other common complex traits,11 a
considerable proportion of the genetic variance in
LDD remains unexplained. While GWA studies do
not capture all variation in the genome, the
approach does offer an agnostic search of the
genome for variants associated with common
complex traits. Their main limitation results from
the inherent multiple testing in their design,
meaning that power is lost and large samples are
needed to address this. In order to optimise sample
size in the present study we performed
meta-analysis of GWAS using a number of cohorts
having the LDD phenotype.
PATIENTS AND METHODS
The cohorts available for inclusion in this study
were all population samples, except Genetics of
osteoARthrosis and Progression study (GARP)
which specifically recruited participants having a
diagnosis of OA. A variable was derived from mea-
sures of disc height and osteophytes obtained from
lateral images on MR, CT scan or plain radiograph.
Summing this variable over the lumbar discs pro-
vided a continuous measure of disc degeneration.
GWA of this summary variable was performed by
each individual study group and summary statis-
tics were sent to and collated by KCL.
Meta-analysis was performed of imputed GWA
data from five population cohorts (Framingham,
GARP, Rotterdam study 1 and 3 and TwinsUK
(TUK)) having imaging of the spine (see below).
All cohorts had obtained fully informed consent
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from their participants and appropriate ethics committee
approval. In all studies, a cumulative degeneration score was
constructed from the sum of scores of degenerative change at
each level (disc space narrowing coded 0–3 and osteophytes,
either anterior or posterior or both, coded 0–3). In those
cohorts where only four disc levels were read (Framingham
Heart study (FHS)), a fifth level was imputed by taking the
mean reading for four discs as a surrogate for the fifth disc, and
summing over five discs. The data underwent inverse normal
transformation to generate a normally distributed variable.
Phenotyping the cohorts
The FHS is a longitudinal cohort of a defined population
in Massachusetts, initiated in 1948 (http://www.
framinghamheartstudy.org). It began as a study sample of 5209
Framingham men and women between the ages of 30 and 60.
Subsequently, offspring and third generation subjects were
incorporated. Every other year, after an extensive baseline
examination, subjects undergo testing that includes a medical
history, blood profile, echocardiogram, and bone, eye and other
tests. The subset of the Framingham subjects covered by the
current analysis comprised 366 subjects from the Offspring and
Generation three arms of the study who had undergone CT
scanning of the spine, and the recruitment, conduct and specifi-
cations of CT scanning have been reported elsewhere.12
Measurement of the lumbar spine CTs for disc height and
scoring (0–3) for anterior and posterior osteophytes was per-
formed by a spine specialist using the mid-sagittal plane at
spinal levels L2-L3, L3-L4, L4-L5 and L5-S1 by author PS using
the atlas of Jarosz et al.7 Using sagittal CT reformatting, the
mid-sagittal plane was determined at each spinal level and mea-
surements of disc height in millimetres were made. The mea-
sured values for disc height (mm) were converted to 0–3
categorical scale for disc height loss. Using an imputed value
for the fifth lumbar disc based on the mean value of the mea-
sured four discs, values for disc height loss and anterior and
posterior osteophytes were summed over five lumbar disc
levels.
The GARP study comprises white sibling pairs of Dutch
origin affected by OA at multiple sites and is aimed at identify-
ing determinants of OA susceptibility and progression.
Probands (ages 40–70 years) and their siblings had OA at mul-
tiple joint sites of the hand or in two or more of the following
joint sites: hand, spine (cervical or lumbar), knee or hip as
described previously.13 Subjects included in this study had
undergone lateral radiographs of the spine (T4-S1). Each inter-
vertebral disc level from L1/2 to L5/S1 was reviewed for the
presence and severity of osteophytes (anterior) and disc narrow-
ing, using the Lane atlas14 where 0=none; grade 1=mild; grade
2=moderate; and grade 3=severe. The score at each level for
anterior osteophytes and disc height loss were summed over
the five lumbar levels.
The Rotterdam study is a prospective population-based
follow-up study of the determinants and prognosis of chronic
diseases in the elderly.15 16 All persons living in Ommoord, a
suburb of Rotterdam, who were aged 55 years and over were
invited to participate. A total of 7983 participants were exam-
ined. For the current analysis, two subsets of the data were
considered. Rotterdam cohort 1 (RS1) consists of 2440 subjects;
Rotterdam cohort 3 (RS3) consists of 974 subjects. Subjects ori-
ginating from the Rotterdam study underwent plain radiog-
raphy and scoring of LDD as previously described.2 In brief,
lateral lumbar radiographs were scored by a single observer for
the presence of the individual radiographic features of disc
degeneration. Each intervertebral disc from L1/2 to L5/S1 was
reviewed for the presence and severity of osteophytes (anterior)
and disc narrowing using the Lane atlas as described above.14
The scores for the two traits over the five lumbar discs were
summed.
The TUK registry was described previously.17 The register was
started in 1993 and now comprises of approximately 10 000
monozygotic and dizygotic adult Caucasian twins aged
16–85 years from all over the UK, plus some parents and sib-
lings. It now incorporates previous twin registries from the
Institute of Psychiatry and Aberdeen University. This is a vol-
unteer sample recruited by successive media campaigns
without selecting for particular diseases or traits. All twins
receive a series of detailed disease and environment question-
naires. The majority of twins have been assessed in detail clin-
ically at several time points for several hundred phenotypes
related to common diseases or intermediate traits. The subset
of TUK covered by the current analysis consisted of 744 sub-
jects who had participated in the spine MR study (scanned
1996–2000) using a Siemens MR machine with (Munich,
Germany) 1.0-tesla superconducting magnet. Serial sagittal
images of the cervical, thoraco-lumbar junction and lumbar
spine (T9-L5) were obtained.7 Images were coded for disc
height loss and anterior osteophytes using a 0–3 scale in each
case, where 0 is normal and 3 maximal degeneration as per the
atlas of Jarosz et al.7 All five lumbar discs were scored and the
scores summed to give a combined LDD variable.
Genotyping and imputation
FHS subjects were genotyped using Affymetrix GeneCHip
Human Mapping 500 K array set (Affymetrix, Santa Clara, CA,
USA) and/or the 100 K array set and/or the 50 K array.
Methods and quality controls have been described previously.18
GARP subjects were genotyped using Illumina Human660W
Quad BeadChips (HumanHap550v3, HumanHap610; Illumina,
San Diego, CA, USA). Genotyping was performed at the geno-
typing Rotterdam Genotyping Centre. Positive strand geno-
types were called by clustering in Genome studio and
imputation was performed using IMPUTE software and
hapmap phase II V.21.19 20 Strict selection criteria were applied
to the measured genotypes using a high information content
(r2 of >95%) and a minor allele frequency >0.0025. Association
analyses were performed using an inhouse developed software
package that allows the analyses of family data using all infor-
mation available in the cases and controls by extending the
Cochran-Armitage trend test.21
RSI and RS3 subjects in the Rotterdam Study sets were geno-
typed on the HumanHap550v3 (RS1) or HumanHap610 (RS3)
Genotyping BeadCHip (Illumina, San Diego, California, USA).
The following sample quality control criteria were applied:
sample call rate >97.5%, gender mismatch with typed X-linked
markers, evidence for DNA contamination in the samples using
the mean of the autosomal heterozygosity >0.33, exclusion of
duplicates or first-degree relatives identified using Identity by
State probabilities and exclusion of outliers (four SD away
from the population mean using multidimensional scaling ana-
lysis with four principal components). Filtering criteria for
imputation are summarised in supplementary table S1.
TUK subjects were genotyped using a combination of
Illumina arrays (Human Hap300 and the Human Hap610Q).
Genotyping was performed by the Wellcome Trust Sanger
Institute using the Infinium assay (Illumina) across three
genome-wide single nucleotide polymorphism (SNP) sets, as
described previously.22 Genotyping results had been sent to
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KCL for collation and analysis using the statistical package,
STATA (StataCorp).23 Strict quality control was applied:
314 075 SNPs were retained for analysis (98.7%); 733 were
excluded because their call rates were ≤90% and 725 SNPs had
minor allele frequency <0.01. In TUK, significant population
substructure was excluded using the STRUCTURE program.24
GWA analysis
All analyses were performed on inverse normal transformed
summary LDD score as described above. Each study performed
GWA analysis for LDD scores using either MACH2QTL (http://
www.sph.umich.edu/csg/abecasis/MACH/index.html) (RS1
and RS3) or SNPTEST (http://www.stats.ox.ac.uk/~marchini/
software/gwas/snptest.html) (GARP), which use genotype
dosage value as continuous additive predictors of LDD score in
a linear regression framework, or ProbABEL25 using an additive
genetic model while accounting for relatedness between the
members of a family. Analysis of imputed genotype data
accounted for uncertainty in each genotype prediction by using
either the dosage information from MACH26 or the genotype
probabilities from IMPUTE.19
Meta-analysis of the five study groups
Genotypes for 2.5–3 million autosomal SNPs were imputed sep-
arately to increase coverage using HapMap V.2 (http://www.
hapmap.org) as the reference panel. In GARP and TUK, imput-
ation was performed with IMPUTE V.219 and in the other
studies with MACH.26 The common reference panel led to the
reporting of results for the positive strand for all cohorts. In add-
ition, allele pairs were compared between cohorts and no detect-
able strand-flips were found; the minor allele frequency was also
compared between datasets. The distributions of β values of the
cohorts were found to be similar and therefore suitable for
meta-analysis. All directly genotyped or imputed autosomal
SNPs having information from more than one study group
(n=2 552 511) were included in the meta-analysis. Association
results were combined using inverse variance weighted fixed
effects meta-analysis using PLINK V.1.06 (http://pngu.mgh.
harvard.edu/purcell/plink/). Two meta-analyses were run: the
first was unadjusted; the second was adjusted for age and sex as
both are known risk factors for LDD and each risk factor was
correlated with LDD in each study group. Heterogeneity of esti-
mated effect was expressed using Q (weighted sum of squares)
and I2 (ratio of true heterogeneity to total observed variation).
SNPs were excluded from the meta-analysis if the cohort-specific
imputation quality, as assessed by r2 (MACH) or Information
Score (IMPUTE) metric, was <0.40. On this basis, one marker
was excluded from the unadjusted association and one from the
adjusted association.
DNA methylation data and analysis
Whole blood DNA methylation levels were obtained for 38
individuals in the TUK cohort using the Illumina
HumanMethylation27 DNA Analysis BeadChip assay, as previ-
ously described.27 The sample included four monozygotic twin
pairs, eight dizygotic twin pairs and 14 unrelated individuals.
At each CpG site within an individual the methylation level
was presented as β, which represents the ratio of intensity
signal obtained from the methylated beads in the array over
the sum of methylated and unmethylated bead signals.
Following quality control checks, we obtained DNA methyla-
tion at three CpG sites in the promoter region of the PARK2
gene within 2kb of the transcription start site. The three
probes (cg15832436, cg21926612 and cg24816866) mapped
uniquely to the human genome (hg18) within two mismatches
(see Bell et al28). We fitted linear mixed effects models to assess
association between DNA methylation levels at the three CpG
sites in the PARK2 promoter and LDD. We regressed the raw
methylation levels on fixed-effect terms including methylation
chip and LDD, and random-effect terms denoting family struc-
ture and zygosity, and compared the association of differen-
tially methylated regions with a null model, which excluded
LDD from the fixed-effects terms. We also repeated the associ-
ation analyses by normalising the methylation values at each
CpG site to N(0, 1).
RESULTS
The study samples for the meta-analysis included 4683 indivi-
duals of European ancestries. Table 1 shows sample size, demo-
graphic characteristics, LDD and lumbar spine imaging method
for each independent cohort. The majority of participants were
female subjects (67.0%) and the samples had a mean age of
57.7 years. Across the cohorts, the mean level of LDD varied
from 0.011 to 3.46, reflecting differences in imaging methods.
However, the variance of the LDD variables was broadly
similar (range 0.958–1.14), as were the distributions of the esti-
mated genetic effect sizes (β). The genotyping and imputation
methods are shown in online supplementary table S1.
Quantile–quantile plots for the unadjusted LDD GWA meta-
analysis are presented in figure 1 (see online supplementary
figure S1, adjusted). Test statistic inflation post meta-analysis,
as measured by the genomic control statistic,29 was low
(λGC unadjusted=1.02; λGC adjusted=1.03). Results of the
unadjusted and adjusted association analyses were broadly
similar, with the p values of the adjusted analysis somewhat
attenuated. A Manhattan plot for the unadjusted analysis is
shown in figure 2 with numeric results in table 2 (unadjusted)
and online supplementary table S2 (adjusted) for SNPs having
p<10−5.
Table 1 Characteristics of the study samples
FHS GARP RS1 RS3 TUK
N 330 192 2440 974 744
Age (years) 54.3 (11.0) 60.3 (7.1) 65.7 (6.7) 54.7 (3.4) 53.6 (8.3)
Women (%) 42.2 79.7 57 59 96.8
BMI (kg/m2) 28.1 (5.1) 26.44 (4.8) 26.3 (3.4) 27.12 (4.6) 24.9 (4.4)
Lumbar spine imaging CT Radiograph Radiograph Radiograph MRI
LDD variable 2.49 (0.97) 0.02 (0.958) 0.006 (0.978) 0.011 (0.965) 3.46 (1.14)
Values are mean (SD) unless specified otherwise.
BMI, body mass index; FHS, Framingham Heart Study; GARP, Genetics of OsteoArthrosis and Progression study; LDD, Lumbar disc degeneration; RS1, Rotterdam study cohort 1;
RS3, Rotterdam study cohort 3; TUK, TwinsUK.
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Four markers achieved genome-wide significance in the
unadjusted GWAS, of which three were on chromosome 6
(rs926849; rs2187689; rs7767277) and an intergenic marker on
chromosome 3 (rs17034687). The results of the meta-analysis
adjusted for age and gender were broadly similar: the strongest
signal was for SNP rs926849. This SNP lies on an intronic
region of the Parkinson protein 2, E3 ubiquitin protein ligase
(PARK2) gene on chromosome 6. A Forest plot of the groups’
results and their meta-analysis is shown in figure 3. Data were
available from four study groups and the range of estimated
minor allele frequencies was 0.23–0.32. Imputation quality was
high for all four studies contributing this SNP (>0.90, table 2)
and the estimated between-study heterogeneity was acceptable
(I2=0%; p(Q)=0.67). The results of a four-study meta-analysis
which excluded GARP show the marker to have p=9.5e−8
(unadjusted). The minor or C allele of rs926849 was associated
with a lower level of LDD implying that the minor allele is pro-
tective. Figure 4 shows a regional plot of both genotyped and
imputed SNPs within 200 Kb of the PARK2 gene, along with
recombination rates.
Two of the other strongly associated SNPs are in perfect
linkage disequilibrium (LD): rs2187689 and rs7767277 on
chromosome 6. Data were available for four studies and the
range of estimated allele frequency was 0.06–0.09. Imputation
quality was high for all four studies (>0.90). Both SNPs are in
strong LD (r2=0.76) with an intronic marker on the prote-
asome subunit, β type 9, large multifunctional peptidase 2 gene
(PSMB9) that is located in the class II region of the major
histocompatibility complex (MHC). Both genotyped and
imputed SNPs within 400 Kb of rs2187689, along with recom-
bination rates, are shown in a regional plot in online
supplementary figure S3. None of these top SNPs is in LD with
known functional SNPs in either PARK2 or PSMB9.
We tested for an association between LDD and DNA methy-
lation variants at three CpG sites in the PARK2 promoter.
A significant association between DNA methylation at CpG
site cg15832436 and LDD (β=8.74×10−4, SE=2.49×10−4,
p=0.006) was observed. The pattern of hypermethylation with
increasing LDD levels was reflected at the remaining promoter
CpG sites; however, these did not reach nominal significance
(cg21926612 β=0.003, p=0.14; cg24816866 β=6.76×10−4,
p=0.39). We repeated the analyses using normalised methyla-
tion levels and observed that the association between
cg15832436 and LDD remained nominally significant.
DISCUSSION
GWA offers an unbiased scan of common genetic variants
(minor allele frequency >5%) and thus may deliver novel var-
iants in genes not hitherto suspected of playing a role in disc
degeneration. This work is among the first to report on a
genome-wide meta-analysis being conducted for LDD. LDD is
an age-related process which occurs in all people to some
extent and may be detected as early as the teenage years.1 LDD
is known to have genetic determinants7 16 and its expression is
also influenced by gender (women develop LDD later), body
mass index30–34 and smoking.35 Occupational factors also play
a small role in LDD.36 37 LDD as determined by MRI has been
implicated in the development of episodes of severe and disab-
ling low back pain.3 We undertook this large meta-analysis in
order to identify novel genetic variants associated with LDD
and to shed light on the underlying pathology of disc
degeneration.
GWA data obtained using differing chip technology may be
readily compared using imputation with HapMap. In total,
2 552 511 overlapping markers were available in each cohort.
We identified four markers having significant association with
the LDD phenotype (p<5×10−8). There was similarity in the
results obtained with and without adjustment for the covari-
ates age and sex. A total of 26 markers had p<10−5 in both
meta-analyses. As expected, results of the adjusted analyses
had slightly attenuated p values (see online supplementary
table S2) which likely reflect the confounding effect of age. In
both analyses, there were multiple associations to the Human
Figure 1 Quantile–quantile plot of observed versus expected
distribution of p values for the genome-wide association (GWA)
meta-analysis. The plots show GWA meta-analysis quantile–quantile
plot of observed against expected results, unadjusted for covariates.
Figure 2 Manhattan plot for meta-analysis of unadjusted
genome-wide association results. Plot shows combined results for the
five studies included in the meta-analysis, unadjusted results. The blue
and red horizontal lines mark the levels of suggestive and likely
significance, respectively.
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Leukocyte Antigen (HLA) region and to markers in PARK2
(Parkinson protein 2, E3 ubiquitin protein ligase). Among the
most significant findings (table 2) is SNP rs926849 that lies at
6q25.2–27 within an intron in the PARK2 gene, a large gene of
1.3 Mb comprising 12 exons. The SNP encodes a change of base
from T to C and is reported to have a minor allele frequency of
0.23–0.34 in dbSNP, which is keeping with the findings in our
study groups (table 2, figures 3 and 4). Although this SNP has
not been directly genotyped by any study group, estimates
suggest imputation to be accurate for rs926849 (range 95%–
99%, table 2). PARK2 encodes a protein called parkin, which is
a component of a multiprotein E3 ubiquitin ligase complex
that mediates the targeting of unwanted proteins for proteaso-
mal degradation. This complex also controls the level of pro-
teins involved in cell activities such as cell division and growth:
it may be a tumour suppressor protein. Parkin is also involved
in mitophagy: it translocates from the cytosol and promotes
the degradation of uncoupled mitochondria.38 Parkin is widely
Table 2 Results of the genome-wide association meta-analysis (unadjusted, showing those SNPs having p<10−5).
MAF Imputation quality*
SNP Chr Gene N RS1 RS3 TUK FHS GARP RS1 RS3 TUK FHS GARP Eff all β SE p Value
rs17034687 3 NA 4429 0.09 0.1 0.05 0.08 NA 0.92 0.93 0.88 0.82 NA C 0.23 0.038 1.82E-09
rs2187689 6 NA 4457 0.08 0.07 0.06 0.09 NA 0.98 0.99 0.95 0.93 NA C 0.23 0.041 2.72E-08
rs7767277 6 NA 4457 0.08 0.07 0.06 0.09 NA 0.98 0.99 0.95 0.93 NA A 0.23 0.041 2.81E-08
rs926849 6 PARK2 3939 0.31 0.32 NA 0.31 0.23 0.98 0.99 NA 0.9 95.04 C −0.13 0.024 3.25E-08
rs7744666 6 NA 4466 0.1 0.09 0.06 0.1 NA 0.99 1 0.97 0.96 NA C 0.2 0.037 5.58E-08
rs11969002 6 NA 4466 0.1 0.09 0.06 0.1 NA 0.99 1 0.97 0.96 NA A 0.2 0.037 5.59E-08
rs6457690 6 NA 4464 0.1 0.09 0.07 0.11 NA 0.98 1 0.96 0.97 NA A 0.19 0.036 9.36E-08
rs1029296 6 NA 4464 0.1 0.09 0.07 0.11 NA 0.98 1 0.96 0.97 NA C 0.19 0.036 9.39E-08
rs6936004 6 NA 4462 0.1 0.09 0.07 0.11 NA 0.98 1 0.96 0.97 NA C 0.19 0.036 1.04E-07
rs3749982 6 NA 4458 0.1 0.09 0.06 0.1 NA 0.99 1 0.96 0.96 NA A 0.19 0.037 1.46E-07
rs9469300 6 NA 4482 0.1 0.09 0.07 0.1 NA 0.99 1 0.92 0.96 NA A 0.19 0.037 1.47E-07
rs10214886 6 NA 4479 0.1 0.09 0.07 0.11 NA 0.98 1 0.92 0.97 NA A 0.19 0.036 2.32E-07
rs10046257 6 NA 4461 0.1 0.09 0.08 0.11 NA 0.98 1 0.96 0.97 NA A 0.19 0.037 3.22E-07
rs4875102 8 NA 4608 0.26 0.26 0.27 0.25 0.29 0.99 0.99 0.95 0.91 97.65 A −0.12 0.024 3.61E-07
rs3019449 6 PARK2 4636 0.32 0.32 0.31 0.31 0.28 0.98 0.98 0.98 0.99 97.18 A −0.12 0.023 3.68E-07
rs1029295 6 NA 3747 0.1 0.09 NA 0.11 NA 0.98 1 NA 0.97 NA C 0.19 0.038 4.58E-07
rs9301951 13 GPC6 4397 0.04 0.04 0.03 0.05 NA 0.96 0.97 0.74 0.78 NA C −0.26 0.054 9.47E-07
rs7896691 10 PFKP 4652 0.1 0.1 0.09 0.13 0.07 0.99 1 0.96 0.67 97.61 C 0.17 0.035 2.02E-06
rs6602024 10 PFKP 4673 0.1 0.1 0.09 0.13 0.07 0.99 1 0.98 0.67 97.62 A 0.17 0.035 2.20E-06
rs1884158 6 PARK2 4491 0.31 0.32 0.31 0.31 NA 0.98 0.99 0.99 0.91 NA C −0.11 0.023 3.56E-06
rs10998466 10 NA 4446 0.01 0.01 0.01 0.02 NA 0.75 0.97 0.73 0.51 NA A −0.53 0.114 3.59E-06
rs17132175 10 PFKP 4659 0.1 0.1 0.09 0.13 0.07 0.98 0.99 0.97 0.63 97.13 C 0.16 0.036 3.73E-06
rs1981483 16 PIGQ 3939 0.42 0.43 NA 0.42 0.47 0.99 0.98 NA 0.44 99.64 A 0.11 0.023 3.75E-06
rs1154053 8 NA 4639 0.17 0.17 0.18 0.16 0.2 0.99 1 0.96 0.89 96.17 C −0.13 0.028 3.99E-06
rs737631 6 PARK2 4303 0.28 0.29 0.23 0.28 NA 0.92 0.91 0.89 0.83 NA A −0.11 0.025 4.32E-06
rs2484990 10 NA 4429 0.01 0.01 0 0.02 NA 0.56 0.82 0.47 0.93 NA C 0.68 0.148 4.39E-06
rs1250307 10 NA 4415 0.01 0.01 0 0.02 NA 0.56 0.82 0.45 0.94 NA A 0.68 0.148 4.39E-06
rs7204439 16 RAB40C 3939 0.42 0.43 NA 0.43 0.47 0.97 0.98 NA 0.43 97.37 C 0.11 0.023 4.43E-06
rs4802666 19 MYH14 4094 0.27 0.27 0.18 0.27 NA 0.7 0.74 0.76 0.64 NA A −0.13 0.029 4.55E-06
rs2484992 10 NA 4440 0.01 0.01 0 0.02 NA 0.56 0.82 0.48 0.93 NA C 0.68 0.149 4.81E-06
rs9488238 6 NA 4464 0.04 0.03 0.02 0.03 NA 0.87 0.88 0.87 0.97 NA A −0.28 0.061 5.17E-06
rs763014 16 RAB40C 3939 0.42 0.43 NA 0.43 0.47 0.98 0.99 NA 0.42 99.4 C 0.1 0.023 5.43E-06
rs1205863 6 NA 3939 0.06 0.06 NA 0.06 0.07 0.99 1 NA 0.99 98.23 G 0.21 0.047 5.64E-06
rs11918654 3 ARL8B 4310 0.27 0.27 0.29 0.27 NA 0.97 0.98 0.9 0.99 NA C −0.11 0.024 7.10E-06
rs4881085 10 PFKP 4490 0.1 0.1 0.1 0.13 NA 1 1 0.99 0.67 NA A 0.16 0.036 7.44E-06
rs2657195 8 NA 4316 0.22 0.21 0.18 0.21 NA 0.85 0.85 0.87 0.74 NA A −0.13 0.028 7.54E-06
rs11754641 6 NA 4478 0.03 0.03 0.02 0.04 NA 0.93 0.95 0.91 1 NA C 0.29 0.064 7.84E-06
rs12805875 11 NA 4674 0.42 0.41 0.42 0.43 0.41 1 1 1 1 98.12 A 0.09 0.021 8.51E-06
rs980238 8 NA 4491 0.3 0.29 0.31 0.29 NA 1 1 1 1 NA A −0.1 0.023 9.11E-06
rs7103004 11 NA 4667 0.42 0.41 0.42 0.43 0.41 1 1 0.99 1 97.09 C 0.09 0.021 9.20E-06
rs4554859 11 NA 4674 0.42 0.41 0.42 0.43 0.41 1 1 1 1 98.12 G 0.09 0.021 9.24E-06
rs7118412 11 NA 4669 0.42 0.41 0.42 0.43 0.41 1 1 0.99 1 97.09 A 0.09 0.021 9.37E-06
rs2017567 16 NA 4683 0.42 0.43 0.42 0.42 0.47 0.99 1 1 0.45 100 C 0.1 0.021 9.38E-06
rs710924 16 PIGQ 4683 0.42 0.43 0.42 0.42 0.47 1 1 1 0.45 99.64 C 0.09 0.021 9.93E-06
*r2 from MACH for RS1, RS3, FHS and GARP; information score from IMPUTE for TUK.
Studies contributing data are denoted.
SNP, single nucleiotide polymorphism; Chr, chromosome; N, number of subjects studied; MAF, minor allele frequency; RS1, Rotterdam study cohort 1; RS3, Rotterdam study
cohort 3; TUK, TwinsUK; FHS, Framingham Heart Study; GARP, Genetics of OsteoArthrosis and Progression study; Eff all, effect allele; β, effect size; SE, SE of β.
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expressed in solid organs as well as skeletal muscle (http://www.
proteinatlas.org/). Mutations within PARK2 are associated with
diverse conditions including autosomal recessive juvenile
Parkinson’s disease, Alzheimer ’s disease, diabetes mellitus and
several solid tumours (reviewed in39). Parkin may account for the
inverse relation between Parkinson’s disease and cancer inci-
dence.40 Our findings of hypermethylation with increasing LDD
score suggest that PARK2 expression is reduced with increasing
disc degeneration but functional studies of intervertebral disc and
other spine tissues are needed.
Three further markers in the unadjusted meta-analysis had
p<5×10−8. Marker rs17034687 is an intergenic marker on
chromosome 3. Based on One Thousand Genomes (1KG)/CEU
data, it is not in LD (r2> 0.3) with any known gene-based
markers. Markers rs2187689 (supplementary figure S2) and
rs7767277 are HLA region markers, neither of which is included
in the 1KG pilot data. Using data from HapMap V.3 (release 2),
rs2187689 and rs776277 are in perfect LD with each other and
in LD (r2= 0.76) with an intronic marker in PSMB9 (prote-
asome (prosome, macropain) subunit, β type 9; large
multifunctional peptidase 2). Proteasomes are distributed
throughout eukaroytic cells at high concentration and cleave
peptides in an ATP/ubiquitin-dependent process in a non-
lysosomal pathway. The gene is located in the class II region of
the MHC. Expression of the gene is induced by interferon γ
and this gene product replaces catalytic subunit 1 (proteasome
β 6 subunit) in the immunoproteasome.
While lumbar degeneration is not considered an inflamma-
tory process and has not been reported to be auto-immune in
aetiology, there is evidence of pro-inflammatory cytokine acti-
vation in herniated lumbar discs41 and anti-TNF has been used
successfully to treat disc herniation-induced sciatica.42 Of note,
the COL11A2 gene lies 169 KB upstream from rs2187689. An
SNP (rs2076311) within this candidate gene has been shown to
be associated with MR determined disc signal intensity in a
candidate gene study of Finnish male twins.43 SNP rs2076311
is not, however, in LD with our top hit, rs2187689 (r2=0.017)
and so it seems unlikely that this collagen-encoding gene
accounts for our observed association. Many published GWA
studies have identified SNPs in intergenic regions and the
Figure 4 Regional plot of association results and recombination rates for the PARK2 gene, unadjusted results. −log10 p values (y-axis) of the single
nucleotide polymorphisms (SNPs) are shown according to their chromosomal positions (x-axis) with lead SNP shown as a purple diamond. The
colour intensity of each symbol depicting an SNP reflects the extent of LD with the rs926849, coloured red (r2>0.8) through to blue (r2<0.2).
Genetic recombination rates (cM/Mb), estimated using HapMap CEU samples, are shown with a light blue line. Physical positions are based on build
36 (NCBI) of the human genome. Also shown are the relative positions of genes mapping to the region of association. Genes have been redrawn to
show the relative positions and, therefore, the maps are not to physical scale.
Figure 3 Forest plot of rs926849 in PARK2 unadjusted for covariates. The contribution of the studies included in the meta-analysis is shown in this
fixed effects model. The C allele is considered. Heterogeneity, I2=0%; p(Q)=0.67. TE, treatment effect; seTE, standard error treatment effect.
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precise role of these regions is yet to be defined. Long range
enhancers, for example, could operate here and so an influence
on COL11A2 expression cannot be ruled out.
Of suggestive significance is SNP rs4802666 (p=3.76×10−6,
adjusted meta-analysis) which lies within the MYH14 gene
which encodes myosin, heavy chain 14, non-muscle. It is
expressed in cell lines derived from bone (http://www.
proteinatlas.org) and is implicated in autosomal dominant
hearing impairment. It is of interest in LDD because it lies on
chromosome 19 under the linkage peak we have reported in
twins for LDD44 and a peak reported by the Framingham
group for hand OA.45 As there is a known relationship between
these two phenotypes, this region on chromosome 19 forms a
highly plausible candidate region for OA. It is not impossible
that a muscle-expressed protein plays a role in LDD through
mechanisms similar to those proposed for OA, considered by
some to be a multi-tissue syndrome rather than simply a
disease of cartilage.46
The main limitation of the study is one of obtaining an
accurate phenotype on individuals which is known to be an
important factor in the success of GWA.47 There is at present
no agreed gold standard imaging method in the determination
of LDD, although it is recognised that MRI offers the most sen-
sitive, widely available tool. Even so, MR is relatively expensive
and many of the largest spine cohorts in the world have plain
radiographs, which offer more limited phenotypic information.
The coding method applied to the imaging is also yet to be for-
mally standardised: our interest in the individual subtraits of
LDD led us to devise a coding method in which they were
separated, as reported previously.7 In order to obtain sufficient
sample size, a number of cohorts contributed having different
imaging methods, but traits were selected to enable comparison
across the cohorts. Thus, study groups recoded their imaging
where necessary to meet uniform requirements for inclusion.
We included measures of disc height (coded 0–3) and anterior
osteophytes in RS1, RS3, GARP and TUK (also coded 0–3) and
posterior osteophytes in FHS (coded 0–3). These subpheno-
types were summed over the five discs and underwent inverse
normal transformation to give a normal distribution. A further
limitation is that four cohorts are population samples while
GARP is derived from OA-affected sibling pairs. We included
GARP because it has made a contribution to similar analyses
performed for OA48 and, with adjustment for relatedness, pro-
vides data comparable with other studies. While the differing
methods of imaging provide different amounts of information
so the LDD variable has lower mean in those cohorts with
radiographs, the variance is comparable. Where GARP samples
made a contribution to the meta-analysis (a number of the
significant SNPs did not include a contribution from GARP,
table 2), the minor allele frequency was similar to those of
other groups. The TUK group has a disproportionate number
of women, for historical reasons. The men were retained,
however, as they did not differ significantly from women in
the LDD variable or body mass index (data not shown). This
study lacks a replication group. A second sample of similar size
to the first is considered important to show that the findings
of the first sample are true positives. Unfortunately there are,
to our knowledge, no other collections of Northern Europeans
having spine imaging which together would approach our
sample size. There is considerable evidence in the literature
that the genetic predisposition between Northern Europeans
and Asians to OA is different49 and, given the similarities
between OA and LDD, we felt replication should be made in
Northern Europeans. We elected to include all the subjects in
a single, powerful study rather than split the sample and
reduce the chances of finding significant novel loci associated
with LDD.
In conclusion, this is the first large-scale GWA study of LDD
and we have identified several novel variants in the PARK2
gene and in PSMB9 within MHC class 2. We have shown in a
small subset that methylation at one of the PARK2 promoters
is associated with MRI determined LDD. Both loci merit
further investigation to shed light on the important clinical
endpoint of low back pain.
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